VIHUMA

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug VIHUMA contains one active pharmaceutical ingredient (API):

1	Coagulation factor VIII UNII U50VWW6XH6 - SIMOCTOCOG ALFA
	Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.
	Read more about Coagulation factor VIII

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VIHUMA Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BD02	Coagulation factor VIII	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1739145, 1739156, 1739167, 1739178, 1787216, 1787227, 1787238
IT	Agenzia del Farmaco	045273012, 045273024, 045273036, 045273048, 045273051, 045273063, 045273075
LT	Valstybinė vaistų kontrolės tarnyba	1082394, 1082395, 1082396, 1082397, 1086901, 1086902, 1086903
PL	Rejestru Produktów Leczniczych	100387600, 100387616, 100387622, 100387639, 100417197, 100417205, 100417211